Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12770
Abstract: Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated… read more here.
Keywords: enzalutamide; prostate cancer; domain; epi 7170 ... See more keywords
Enzalutamide in Patients With Castration‐Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2016.06.011
Abstract: Micro‐Abstract Therapeutic options for metastatic castration‐resistant prostate cancer have considerably changed in the past decade. In this retrospective analysis of patients included in the Swiss Enzalutamide Named Patent Program, we analyzed the outcome of patients… read more here.
Keywords: prostate; analysis; enzalutamide; castration resistant ... See more keywords
Adoption of Abiraterone and Enzalutamide by Urologists.
Sign Up to like & getrecommendations! Published in 2019 at "Urology"
DOI: 10.1016/j.urology.2019.05.012
Abstract: OBJECTIVE To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. METHODS… read more here.
Keywords: enzalutamide urologists; abiraterone enzalutamide; enzalutamide; adoption abiraterone ... See more keywords
Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results
Sign Up to like & getrecommendations! Published in 2017 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyw187
Abstract: Abstract Longer term efficacy results in Japanese patients enrolled in PREVAIL demonstrate continued treatment benefit of enzalutamide compared with placebo in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer. read more here.
Keywords: prostate cancer; japanese patients; enzalutamide; metastatic castration ... See more keywords
Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0270803
Abstract: Enzalutamide, a nonsteroidal antiandrogen, significantly prolonged the survival of patients with metastatic castration-resistant prostate cancer (CRPC). However, patients receiving enzalutamide frequently develop drug resistance. Rooibos (Aspalathus linearis) is a shrub-like leguminous fynbos plant endemic to… read more here.
Keywords: proliferation; prostate; enzalutamide resistant; pca ... See more keywords